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Abstract
Diabetic nephropathy is the commonest microvascular complication in both types 1 
and 2 diabetes mellitus. Disease pathogenesis is based on a multifactorial interaction 
between metabolic and hemodynamic factors. In response to hyperglycemia, which 
disrupts the body’s metabolic milieu, a cascade of complex molecular events occur 
leading to glomerular hypertrophy, tubular inflammation, mesangial expansion, oxi-
dative stress, and renal fibrosis. Beyond the conventional microalbuminuria, which can 
predict disease onset, novel biomarkers are now proving more reliable as predictive 
tools. While several reports show that glomerular and tubular biomarkers are more 
sensitive than microalbuminuria, tubular markers specifically constitute earlier predic-
tors of the disease. Similarly, biomarkers of inflammation and oxidative stress have 
been demonstrated as dependable diagnostic tools. As an important cause of mortality 
from end-stage renal disease (ESRD), diabetic nephropathy constitutes an important 
challenge in diabetic care. Interestingly, strict glycemic control assessed by glycated 
hemoglobin (Hb A1 c) estimates, and antihypertensive therapy with angiotensin-
converting enzyme inhibitors/angiotensin-receptor blockers (ACEI/ARB) ± calcium-
channel blockers form the main strategies for preventing its onset and slowing down 
its progression. Other strategies include uric acid antagonist, and renin and endothelin 
inhibitors. This book chapter discusses these predictive tools and possible preventive 
strategies.
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1. Introduction
Type 1 diabetes mellitus is the usual form of diabetes mellitus in children. However, type 2 
diabetes mellitus is now observed among them as well, especially in adolescents: with obesity 
as a putative risk factor. Diabetic nephropathy is the commonest microvascular complication 
of the kidney in both types of diabetes mellitus [1]. It is a clinical syndrome characterized by 
persistent macroalbuminuria (or urine albumin excretion rate of ≥200 μg/min) recorded at 
least twice within a 3- to 6-month interval, progressive decline in glomerular filtration rate 
(GFR), and hypertension [2]. The presence of microalbuminuria (urine albumin excretion rate 
of ≤199 μg/min) in type 1 diabetes mellitus is not only strongly predictive of macroalbumin-
uria (overt diabetic nephropathy) and subsequent end-stage renal disease (ESRD) but also 
constitutes a risk factor for future cardiovascular disease [3]. Contrary to the previously-held 
view that diabetic nephropathy is rare in childhood [4], some reports indicate that the dis-
ease can actually occur in the pediatric age group [5–7]. While the development of diabetic 
nephropathy can occur over a period of 10–20 years, beginning with microalbuminuria and 
ending with ESRD [1], it is currently projected that the rate of progression from microalbu-
minuria to macroalbuminuria over a 5- to 10-year period is about 15–30%, and may increase 
to 45% in patients with up to 15 years of diabetes duration [8].
Although microalbuminuria has traditionally remained the gold-standard biomarker for 
predicting diabetic nephropathy, its draw-backs include the following. Firstly, not all microal-
buminuric diabetics will end up with diabetic nephropathy and ESRD [9, 10]. Secondly, micro-
albuminuria can only occur in the presence of significant renal injury since it is preceded by the 
appearance of several tubular and glomerular biomarkers in urine [11]. Thirdly, many diabetic 
patients with diabetic nephropathy can revert to normoalbuminuria, and these patients can 
also present with a reduction in GFR without progressing from normo- to macroalbuminuria 
(the concept of ‘non-albuminuric’ diabetic nephropathy) [12]. Thus, in place of microalbumin-
uria, these novel biomarkers are now increasingly used as earlier predictors of the disease.
In this book chapter, the use of biomarkers as predictive tools of diabetic nephropathy, and 
the preventive strategies against its onset and progression to ESRD are discussed.
1.1. Pathogenesis of diabetic nephropathy: a synopsis
In response to hyperglycemia, which disrupts the body’s metabolic milieu, a cascade of com-
plex molecular events occur resulting in the key pathogenic components of diabetic nephrop-
athy, namely glomerular hypertrophy, tubular inflammation, mesangial expansion, oxidative 
stress, and renal fibrosis; several activated pathways individually or collectively influence the 
onset and progression of this disease [13]. However, it is important to note that genetic pre-
disposition also contributes to the development of diabetic nephropathy because only 30–40% 
of diabetic patients develop diabetic kidney disease irrespective of glycemic control [14, 15].
In fact, the pathogenesis of the disease is based on a multifactorial interaction between meta-
bolic and hemodynamic factors [16]. Metabolic factors involve glucose-dependent pathways, 
such as advanced glycation end-products and their receptors while hemodynamic factors 
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consist of several vasoactive hormones, such as components of the renin–angiotensin system 
[16]. It is postulated that these metabolic and hemodynamic factors interact through common 
molecular and signaling pathways, such as protein kinase C leading to generation of reac-
tive oxygen species. Presumably, these contributing factors result in pathological damage 
not only to the glomerulus, especially the podocytes, but also to the tubulo-interstitium. In 
other words, hyperglycemia induces vascular injury through complex overlapping pathways, 
comprising formation of advanced glycation end-products, activation of protein kinase C and 
generation of reactive oxygen species, which might play a key role in the initiation and pro-
gression of diabetic nephropathy [17].
Specifically, resident and nonresident cells of the kidney are stimulated by hyperglycemia to 
produce humoral mediators, cytokines, and growth factors which are implicated in the struc-
tural alterations such as increased deposition of extracellular matrix protein at the glomerulus, 
and functional alterations such as hyperpermeability of the glomerular basement membrane 
or shear stress [15]. Increased deposition of extracellular matrix protein results in basement 
membrane thickening and mesangial expansion while glomerular hyperpermeability leads to 
progressive albuminuria, which is one of the hallmarks of the disease (Figure 1).
1.2. Novel biomarkers as predictive tools for diabetic nephropathy
Novel biomarkers are now useful tools for predicting the onset and progression of diabetic 
nephropathy. Attempts have been made at classifying these biomarkers into major groups, 
although these groups overlap with one another. Representative groups include glomeru-
lar biomarkers; tubular biomarkers; biomarkers of inflammation; biomarkers of oxidative 
stress; and miscellaneous biomarkers [18]. Examples of each group of biomarkers include 
albumin, transferrin, laminin, immunoglobulin G, fibronectin, ceruloplasmin, type IV col-
lagen, lipocalin-type prostaglandin synthase (L-PGDS), and glycosaminoglycans which 
make up the glomerular biomarkers; neutrophil gelatinase-associated lipocalin (NGAL), 
cystatin C, kidney molecule injury 1 (KIM-1), liver-type fatty acid binding protein (L-FABP), 
Figure 1. Pathogenetic pathway of albuminuria in diabetic nephropathy. GBM= glomerular basement membrane, EMP= 
extracellular matrix protein.
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N-acetyl-β-D-glucosaminidase (NAG) and α-1-microglobulin constitute the tubular biomark-
ers; tumor necrosis factor-α (TNF-α), interleukin-1β, interleukin-8, interleukin-18, monocyte 
chemoattractant protein-1 (MCP-1), eotaxin, orosomucoid, RANTES and granulocyte colony-
stimulating factor (G-CSF) represent the biomarkers of inflammation; 8-oxo-7,8-dihydro-
2-deoxyguanosine (8oHdG) is a typical example of a biomarker of oxidative stress; nephrin, 
podocalyxin, advanced glycation end products (AGEs), vascular endothelial growth factor 
(VEGF), heart fatty-acid binding protein (H-FABP) and retinol-binding protein are listed as 
miscellaneous biomarkers. However, the overlap of the groups with one another shows that 
some miscellaneous biomarkers such as podocalyxin, nephrin and VEGF are also considered 
as glomerular biomarkers, whereas H-FABP and retinol-binding protein can be regarded as 
tubular biomarkers as well. Similarly, some biomarkers of inflammation such as TNF-α, the 
interleukins and MCP-1 are also identified as tubular biomarkers.
1.2.1. Glomerular biomarkers versus albuminuria
Several studies have provided evidence which indicate that novel glomerular biomarkers are 
more sensitive predictors of diabetic nephropathy compared to albuminuria, which has been 
considered as the conventional biomarker of glomerular injury (Table 1).
Firstly, urine transferrin, which is highly sensitive as a biomarker of diabetic nephropathy 
[19, 20], conversely has poor specificity for the disease because of confounders like primary 
Glomerular biomarkers Predictive ability for diabetic nephropathy
• Microalbuminuria • Traditional biomarker predicting glomerular injury in T1DM and 
T2DM
• Urine transferrin • High sensitivity
• Poor specificity
• More sensitive than microalbuminuria in predicting diabetic nephropa-
thy in T2DM
• Urine ceruloplasmin • High sensitivity
• More sensitive than microalbuminuria
• Urine type IV collagen • High sensitivity
• More sensitive than microalbuminuria
• Early predictor of diabetic nephropathy in T2DM
• Can differentiate diabetic nephropathy from non-diabetic nephropathy
• Urine laminin • Similar predictive ability with urine type IV collagen
• Appears before microalbuminuria in T1DM
• Urine fibronectin • Higher excretion in microalbuminuric than normoalbuminuric T2DM 
patients
• Degradation products correlate with albuminuria
T1DM = type 1 diabetes mellitus, T2DM = type 2 diabetes mellitus.
Table 1. Glomerular biomarkers versus microalbuminuria as predictive tools for diabetic nephropathy.
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glomerulonephritis and systemic diseases affecting the glomerulus, which also present with 
transferrinuria [21]. However, the biomarker is considered more sensitive than albuminuria. For 
instance, some authors have reported that, in the pre-albuminuric phase, transferrinuria was higher 
in diabetic subjects than in healthy controls [22, 23]. These findings underscore the superiority of 
urine transferrin over urine albumin excretion in the early prediction of diabetic nephropathy.
Secondly, urine ceruloplasmin is poorly filtered through the glomerular barrier because of its 
negative charge. Similar to urine transferrin, this biomarker can predict diabetic nephropathy 
earlier than albuminuria in patients with type 2 diabetes mellitus [24]. It has also been noted that 
urine ceruloplasmin together with urine transferrin, immunoglobulin G and orosomucoid are 
simultaneously elevated prior to the onset of microalbuminuria in type 2 diabetic patients [25].
Another remarkable glomerular biomarker is type IV collagen: a component of the glomerular 
basement membrane and mesangial matrix. Urine type IV collagen has been reported as a more 
sensitive marker of renal injury than urine albumin in patients with type 2 diabetes mellitus 
[26]. It can therefore serve an early predictor of diabetic nephropathy. Furthermore, urine type 
IV collagen can potentially differentiate diabetic nephropathy from non-diabetic nephropathy 
because studies show that type 2 diabetics with nephropathy have a significantly higher type IV 
collagen/albumin ratio in comparison with their non-diabetic cohorts with nephropathy [27, 28].
Laminin, a component of the glomerular basement membrane, is a biomarker with similar 
predictive properties as type IV collagen [29]. For instance, urine laminin can also discriminate 
between diabetic and non-diabetic nephropathy as one report showed that type 2 diabetics 
with nephropathy had significantly higher laminin/albumin ratio in comparison to patients 
with non-diabetic nephropathy [27]. More importantly, some investigators have documented 
a higher urine laminin excretion in pediatric patients with type 1 diabetes mellitus when 
juxtaposed with their healthy controls, even before the appearance of microalbuminuria [30].
Another glomerular biomarker worthy of mention is fibronectin. It is basically an intrinsic 
component of the glomerular extracellular matrix. Interestingly, urine fibronectin is report-
edly higher in diabetic patients compared to their controls, with a significant difference noted 
only in macroalbuminuric patients [31, 32]. Further evidence supporting the predictive role of 
urine fibronectin in diabetic nephropathy include its higher excretion in type 2 diabetics with 
microalbuminuria than in those with normoalbuminuria [33], as well as the correlation of its 
degradation products with albuminuria [34].
1.2.2. Tubular biomarkers versus albuminuria
When compared to microalbuminuria and other novel glomerular biomarkers, tubular bio-
markers are early predictors of diabetic nephropathy because tubulointerstitial lesions are 
known to occur much earlier in the course of the disease and may actually precede glomerular 
injury [35]. This characteristic has given this group of biomarkers an edge over glomerular 
biomarkers as earlier predictors of diabetic nephropathy.
For instance, studies on NGAL as a biomarker have revealed these interesting findings: 
presence of its elevated urine levels in diabetic patients with normoalbuminuria and its use 
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in evaluating tubular lesions in the disease [36], its occurrence before microalbuminuria in 
patients with type 1 diabetes mellitus [37, 38], as well as its role in predicting the progression 
of diabetic kidney disease in type 2 diabetics [39, 40]. Thus, NGAL may have a better predic-
tive ability for diabetic nephropathy than microalbuminuria.
Secondly, α-1-microglobulin has been identified as an affordable tubular biomarker for the 
early prediction of diabetic nephropathy [41]. Although α-1-microglobulin undergoes glo-
merular filtration, its tendency for proximal tubular reabsorption ensures its increased urine 
excretion in tubular dysfunction because of impaired reabsorption. In type 2 diabetics with 
normoalbuminuria, some authors were able to demonstrate increased urine levels of this 
biomarker because, as previously mentioned, tubular injury precedes the onset of microalbu-
minuria in diabetic nephropathy [42].
On the other hand, there appears to be divergent findings on the usefulness of NAG as a bio-
marker in the evaluation of diabetic nephropathy. Whereas some authors reported its clinical 
insignificance as an early biomarker of the disease [43], other reports conversely show that it 
remains a sensitive tubular biomarker for early detection of renal lesions in patients with both 
type 1 and 2 diabetes mellitus, as its urinary excretion can occur before microalbuminuria [44–46].
Furthermore, increased urine L-FABP levels have been observed in type 1 diabetics with 
normoalbuminuria, and is capable of not only predicting the onset of microalbuminuria but 
also its progression to macroalbuminuria [47]. Type 2 diabetics with normoalbuminuria also 
present with increased urine levels of this biomarker, which underscores its predictive ability 
for the onset and progression of diabetic nephropathy [48, 49].
Finally, some authors have reported the predictive ability of cystatin C for the progression 
of diabetic nephropathy [50], as well as its role in the evaluation of early nephropathy in 
type 2 diabetes mellitus [51], while increased urine KIM-1 levels have been observed more 
in diabetic patients with microalbuminuria than in those with normoalbuminuria [52]. This 
again suggests that tubular injury occurs early in the pathophysiologic trajectory of diabetic 
nephropathy.
1.2.3. Biomarkers of inflammation
Interestingly, the role of TNF-α (a pro-inflammatory cytokine) in the development of dia-
betic nephropathy is well documented [53–55]. The predictive ability of this cytokine as a 
biomarker for the disease is predicated upon the observations of its increased urine levels in 
diabetic patients who have albuminuria, as well as the significant rise of its urinary excretion 
during progression of diabetic nephropathy [54]. In fact, elevated urine TNF-α excretion and 
TNF-α levels in renal interstitial fluid have been noted to precede a significantly raised albu-
minuria in experimental diabetic rats [56]. This is corroborated by other studies which report 
a direct association between albuminuria and serum TNF-α in diabetic patients with normal 
renal function and microalbuminuria on one hand, as well as in those with macroalbuminuria 
and ESRD on the other hand [57, 58]. Similarly, other biomarkers of inflammation such as 
IL-8, MCP-1, G-CSF, eotaxin, and RANTES are reportedly higher in microalbuminuric type 2 
diabetics than in their normoalbuminuric counterparts [59]. In type 1 diabetes mellitus, urine 
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orosomucoid was also noted to be raised in normoalbuminuric patients when compared to 
non-diabetic controls: with increasing levels reported in microalbuminuric and macroalbu-
minuric diabetic patients [60].
1.2.4. Biomarkers of oxidative stress
8oHdG is the prototype of this group of biomarkers. This molecule is actually a product of oxi-
dative injury to DNA which appears unchanged in the urine. It may represent a dependable 
clinical biomarker for predicting the onset of diabetic kidney disease because some authors 
have observed that patients whose nephropathy progressed significantly had higher urinary 
excretion of this biomarker than those who had lower or moderate urinary excretion [61].
2. Preventive strategies for diabetic nephropathy
Generally, strict glycemic control and painstaking control of hypertension have significant 
impact on prevention and progression of diabetic nephropathy; a finding noted in adult 
patients with type 2 diabetes mellitus [62]. In children and adolescents, who are predomi-
nantly type 1 diabetics, these measures should be equally applicable as preventive strategies. 
More importantly, strategies that target the modifiable risk factors for diabetic nephropathy 
may result in better outcomes. Some of the modifiable and non-modifiable risk factors include 
poor glycemic control, pubertal growth spurt, hypertension, hyperlipidemia, smoking habits, 
albuminuria, obesity and genetic predisposition [6, 63–66]. For instance, in type 1 diabetes 
mellitus, strict glycemic control is the major preventive strategy for diabetic nephropathy, 
whereas in type 2 diabetes mellitus, modulation of hypertension, dyslipidemia, and obesity 
(modifiable risk factors) constitute important strategies [63]. Notably, the current recom-
mendations/strategies for preventing the onset and retarding the progression of diabetic 
nephropathy are essentially evidence-based, and are summarized in Table 2.
Firstly, the measurement of hemoglobin A1 c (Hb A1 c) has been adopted as a reliable tool for 
assessing glycemic control. It is a marker for average glycemic levels over the previous 3 months. 
The goal of glycemic control is basically to maintain Hb A1 c level of less than 7% while avoiding 
hypoglycemia. In fact, strict glycemic control reduces the risk of microvascular complications in 
both type 1 and type 2 diabetes mellitus [67, 68]. Reports show that diabetic nephropathy rarely 
occurs when the Hb A1 c level is consistently less than 7.5–8.0% [2, 65]. Notably, results of two 
major clinical trials have buttressed the effectiveness of tight glycemic control as a preventive 
strategy [68, 69]. In one of the studies conducted on type 2 diabetics, there was a 34% reduction 
in the risk of microalbuminuria [68], while in type 1 diabetics, the incidence of microalbuminuria 
was decreased by 39% in the primary prevention group with a 54% reduction in its progression 
to macroalbuminuria in the secondary prevention group [69].
Secondly, the control of hypertension is renoprotective in type 1 and type 2 diabetes mellitus, 
as it reduces albuminuria and delays the onset of nephropathy [70]. The renin-angiotensin 
system constitutes the target of the most effective strategy for blood-pressure control and 
for reducing the pathophysiologic abnormalities which lead to albuminuria. Specifically, it 
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does appear that blood pressure elevation directly correlates with the degree of albuminuria 
in type 2 diabetes mellitus [71]. Thus, antihypertensive therapy, especially with angiotensin 
converting enzyme inhibitors (ACEI) or in combination with other antihypertensive agents, 
is an effective strategy for preventing the progression of diabetic nephropathy [71]. While 
either ACEI or angiotensin-II type 1 receptor blockers (ARB) is recommended in patients with 
microalbuminuria and type 2 diabetes mellitus [72], none of them is recommended in nor-
motensive, normoalbuminuric diabetics for the primary prevention of diabetic nephropathy. 
Apart from ACEI which are regarded as first-choice treatment for hypertension in diabetics, 
other effective alternative antihypertensive drugs include calcium-channel blockers: either 
alone [73], or in combination with ACEI [74].
Thirdly, the use of novel treatments has been tried as strategies for preventing the onset and 
progression of diabetic nephropathy. These therapeutic agents include the following: vitamin 
D, allopurinol (uric acid antagonist), aliskiren (renin inhibitor), and atrasentan (endothelin 
antagonist or l inhibitor) [75–78]. In experimental murine models, vitamin D is thought to acti-
vate an antioxidant pathway and ameliorate diabetic nephropathy by reducing albuminuria 
[75]. Furthermore, vitamin D deficiency is known to be a common disorder in diabetics and 
probably constitutes a risk factor for ischemic heart disease, worsening of chronic kidney dis-
ease and diabetic nephropathy [79]. Vitamin D metabolites may inhibit the renin-angiotensin 
system and exert renoprotective effect by preventing glomerulosclerosis and reducing albu-
minuria in diabetic nephropathy; in addition, administering the vitamin is reported to have 
resulted in a reduction in insulin resistance and blood pressure [80, 81]. In fact, findings from 
several studies support the beneficial effect of dietary or supplemental vitamin D in retarding 
the progression of diabetic nephropathy through reduction of albuminuria [82–85]. Another 
Preventive strategies Mechanism of action
• Strict or tight glycemic control • Reduces risk of microalbuminuria
• Reduces progression of microalbuminuria to 
macroalbuminuria
• Antihypertensive therapy with ACEI/ARB ± calcium-
channel blockers
• Reduces albuminuria and delays the onset of diabetic 
nephropathy
• Prevents progression of diabetic nephropathy in 
microalbuminuric patients
• Vitamin D • Ameliorates nephropathy by reducing albuminuria
• Allopurinol (uric acid antagonist) • Reduces urinary TGF-β in diabetic nephropathy
• Aliskiren (renin inhibitor) • Reduces albuminuria and serves as an antihyperten-
sive in T2DM
• Atrasentan (endothelial inhibitor) • Reduces residual albuminuria in type 2 diabetic 
nephropathy
• Dietary protein/phosphate restriction • Retards progression of diabetic nephropathy
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor blocker, TGF-β = transforming growth 
factor-beta, T2DM = type 2 diabetes mellitus.
Table 2. Preventive strategies for the onset and progression of diabetic nephropathy: an evidence-based summary.
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novel therapeutic agent- allopurinol- was reported to reduce albuminuria in patients with 
type 2 diabetes [86]. Evidence point to a greater serum uric acid level in patients with diabetic 
nephropathy than in normal subjects [87]. Uric acid specifically plays a mediatory role in 
the pathogenesis of diabetic nephropathy, as it leads to endothelial dysfunction, increased 
activity of the renin-angiotensin-aldosterone system (RAAS), and induction of inflammatory 
cascades, as well as profibrotic cytokine activation which synergistically contribute to pro-
gression of microvascular disease and extracellular matrix deposition; these events result in 
kidney injury in diabetic nephropathy [87]. Obviously, hyperuricemia may thus impair glo-
merular function, and promote albuminuria. Interestingly, allopurinol has also been observed 
to reduce urinary transforming growth factor-beta (TGF-β) in diabetic nephropathy, apart 
from improving endothelial dysfunction [76]. Furthermore, the direct renin inhibitor-aliski-
ren-reportedly reduces albuminuria and also serves as an antihypertensive in type 2 diabetes 
mellitus either as a monotherapy [77], or in combination with an angiotensin receptor blocker 
(ARB) [88]. Endothelin-1 is regarded as the most potent vasoconstrictor which plays a role in 
renal regulation of fluid and salt balance. More importantly, excessive renal production of 
endothelin-1 is associated with proteinuria and tubulointerstitial injury [89]. Although trials 
are still going on to validate the endothelin antagonist or inhibitor (atrasentan), this novel 
agent has been shown to lower residual albuminuria in type 2 diabetic nephropathy besides 
its antihypertensive action [78].
Finally, dietary modification has proved to be an effective tool in retarding the progression of 
diabetic nephropathy. In diabetics, high dietary protein has renal hemodynamic effects which 
comprise elevated GFR, hyperfiltration, and raised intraglomerular pressure which are prob-
ably accentuated by poor glycemic control [79]. Thus, it has been observed that dietary protein 
restriction slows down the deterioration of kidney function in type 1 and type 2 diabetes mellitus 
[90, 91]. For instance, a prospective study which compared type 1 diabetics placed on dietary 
protein/phosphate restriction with those on unrestricted diet revealed a differential reduction 
in GFR, as the GFR in the former group was progressively reduced by only 0.26 ml/min/month 
compared with 1.01 ml/min/month seen in the latter group [92].
3. Conclusion
Both glomerular and tubular biomarkers are sensitive predictors of diabetic nephropathy 
when compared to microalbuminuria, with tubular biomarkers serving as earlier predictors 
of the disease. Other groups of novel biomarkers have also been shown to be effective predic-
tive tools. As the major microvascular complication of both type 1 and type 2 diabetes mel-
litus and an important cause of ESRD-related mortality, the onset and progression of diabetic 
nephropathy therefore constitute an important challenge in diabetic care. Fortunately, strict 
glycemic control and antihypertensive therapy with ACEI/ARB ± calcium-channel blockers 
form the main strategies for preventing the onset and slowing the progression of diabetic 
nephropathy. Other novel treatment options include dietary protein restriction, use of vita-
min D, uric acid antagonist, as well as renin and endothelin inhibitors. As newer strategies 
emerge, prospects for better outcomes in diabetic nephropathy are getting brighter.
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